Myricx Pharma ('Myricx'), a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer today unveiled an initial £4.5 million in seed financing from experienced venture investors, Sofinnova Partners and Brandon Capital Partners.
Maina joined Sofinnova Partners in January 2018. Maina has a long track record as a successful healthcare investor. Prior to joining, she was Director of Healthcare Investment at Touchstone Innovations (formerly Imperial Innovations) in London (UK) since 2006. She has led or co-led numerous investments and sat on the Board of a number of UK biotech companies, such as Autifony, Cellmedica, Psioxus Therapeutics, Pulmocide, Topivert Pharma, Puridify (sold to GE), Thiakis (sold to Wyeth) and Respivert (sold to J&J). Previously, she worked in the R&D teams of several UK and US biotech companies, including Celltech, Oxford Glyco Sciences, Chimeric Therapies and GeneMedicine.
As a long-standing member of the biotech ecosystem, Maina has received strong professional and institutional recognition; and was named one of UK’s Top women in Biopharma several years in a row.
Maina has a BSc from the University of Texas at Austin (United States) and an MBA from the Imperial Business School in London (United Kingdom).